Table 2 Baseline characteristics of study population
Patient Characteristics | N (%) |
|---|---|
GENERAL DEMOGRAPHICS | |
 Patients identified with diabetes | 7168 |
 Mean age (SD) | 64.8 (14.7) |
 Male sex | 3663 (51.1) |
 BMI (kg/m2) (n = 4256) | |
   < 25 | 501 (11.8) |
  25–30 | 1176 (27.6) |
   > 30 | 2579 (60.6) |
LABS | |
 Hemoglobin A1c (n = 6047) | |
  ≤ 7% | 3436 (56.8) |
   > 7 - ≤ 8% | 1383 (22.9) |
   ≥ 8 - ≤ 9% | 631 (10.4) |
   > 9% | 597 (9.9) |
  Not Available | 1121 (15.6) |
 Blood Pressure (n = 4141) | |
   < 130/80 mmHga | 2571 (62.1) |
  ≥130/80 mmHg | 1570 (37.9) |
  Not available | 3027 (42.2) |
 LDL-C (n = 3767) | |
   ≤ 2 mmol/L | 1708 (45.3) |
   > 2 mmol/L | 2059 (54.7) |
  Not Available | 3, (47.4) |
COMORBIDITIES | |
 CVD or Heart Failure | 680 (9.5) |
 CKD | 1281 (17.9) |
  Stage 1b | 19 (1.5)c |
  Stage 2 | 54 (4.2) |
  Stage 3a/b | 1073 (83.8) |
  Stage 4 | 111 (8.7) |
  Stage 5 | 24 (1.9) |
 CVD/Heart failure and CKDd | 234 (3.3) |
MEDICATION USE | |
 Anti-hyperglycemic use | |
  Yes | 4377 (61.0) |
  No/Not Available | 2791 (39.0) |
 Insulin use (N = 7168) | |
  Yes | 1077 (15.0) |
  No/Not Available | 6091 (85.0) |